Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2033-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this post-marketing study is to further characterize the long-term outcome of
known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as
[177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also
seeks to further characterize (as possible) any other serious adverse reaction(s) in the
long-term in adults with prostate cancer who received at least one dose of AAA617 from
interventional, Phase I-IV Novartis sponsored clinical trials.